Purpose: Perioperative treatment of gastric and gastroesophageal junction (G/GEJ) cancer is evolving towards multimodal strategies incorporating HER2-targeted therapy, immunotherapy and chemotherapy. Disitamab vedotin (RC48), an HER2-targeted antibody–drug conjugate, shows promising antitumour activity and potential synergy with immune checkpoint inhibitors. This study evaluated neoadjuvant RC48 combined with camrelizumab and S-1 in resectable HER2-overexpressing locally advanced G/GEJ adenocarcinoma.
Methods: Patients with histologically confirmed HER2-overexpressing (IHC 3+ or 2+) resectable G/GEJ cancer staged as cT3-4aN1-3M0 were enrolled in this prospective single-arm phase II study. Patients received three 3-weekly cycles of RC48, camrelizumab and S-1 before surgery. Pathological complete response (pCR) was defined as the primary endpoint, whereas major pathological response (MPR), objective response rate (ORR), tumour downstaging, disease-free survival (DFS), overall survival (OS) and safety were evaluated as secondary endpoints. Exploratory circulating tumour DNA (ctDNA) methylation profiling (PredicineEPIC) assessed molecular response dynamics and ERBB2 copy number variation.
Results: From 18 September 2022 to 12 December 2024, 32 patients were enrolled; 24 proceeded to D2 resection. The ORR after neoadjuvant therapy was 80.0% (24/30). In the surgical cohort, pCR and MPR were achieved in 25.0% (6/24) and 45.8% (11/24) of patients, respectively, with an R0 resection rate of 100%. The median DFS and OS were not reached at the time of analysis. In the ctDNA substudy (n = 14), methylation-derived tumour fraction declined during therapy and ERBB2 plasma copy number gain aligned with tissue HER2 status. Treatment-related adverse events of grade ≥3 were reported in 31.3% of patients.
Conclusion: Neoadjuvant RC48 combined with camrelizumab and S-1 showed potential antitumour activity with an acceptable safety profile in HER2-overexpressing locally advanced resectable G/GEJ adenocarcinoma.
Key points:
| [1] |
He F, Wang S, Zheng R, et al. Trends of gastric cancer burdens attributable to risk factors in China from 2000 to 2050. Lancet Reg Health West Pac. 2024; 44:101003.
|
| [2] |
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74: 229-263.
|
| [3] |
Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024; 4: 47-53.
|
| [4] |
Sundar R, Nakayama I, Markar SR, et al. Gastric cancer. Lancet. 2025; 405: 2087-2102.
|
| [5] |
Huang C, Liu H, Hu Y, et al. Laparoscopic vs open distal gastrectomy for locally advanced gastric cancer: five-year outcomes from the CLASS-01 randomized clinical trial. JAMA Surg. 2022; 157: 9-17.
|
| [6] |
Hyung WJ, Yang HK, Park YK, et al. Long-term outcomes of laparoscopic distal gastrectomy for locally advanced gastric cancer: the KLASS-02-RCT randomized clinical trial. J Clin Oncol. 2020; 38: 3304-3313.
|
| [7] |
Ojima T, Nakamura M, Hayata K, et al. Short-term outcomes of robotic gastrectomy vs laparoscopic gastrectomy for patients with gastric cancer: a randomized clinical trial. JAMA Surg. 2021; 156: 954-963.
|
| [8] |
Pentheroudakis G, Committee EG. Recent eUpdates to the ESMO Clinical Practice Guidelines on hepatocellular carcinoma, cancer of the pancreas, soft tissue and visceral sarcomas, cancer of the prostate and gastric cancer. Ann Oncol. 2019; 30: 1395-1397.
|
| [9] |
Wang FH, Zhang XT, Tang L, et al. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2023. Cancer Commun. 2024; 44: 127-172.
|
| [10] |
Zhang X, Liang H, Li Z, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): final report of a randomised, open-label, phase 3 trial. Lancet Oncol. 2025; 26: 312-319.
|
| [11] |
Yang Z, Chen R, Li R, Li Y. Research progress in clinical trials of pressurized intraperitoneal aerosol chemotherapy for advanced gastric cancer with peritoneal metastasis. Holistic Integr Oncol. 2025; 4, 68.
|
| [12] |
Zhang X, Liang H, Li Z, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 2021; 22, 1081-1092.
|
| [13] |
Meric-Bernstam F, Johnson AM, Dumbrava EEI, et al. Advances in HER2-targeted therapy: novel agents and opportunities beyond breast and gastric cancer. Clin Cancer Res. 2019; 25, 2033-2041.
|
| [14] |
Zhang XN, Gao Y, Zhang XY, et al. Detailed curriculum vitae of HER2-targeted therapy. Pharmacol Ther. 2023; 245, 108417.
|
| [15] |
Cheng J, Cai M, Wang G, Tao K. HER2 becomes a novel survival biomarker for gastric cancer patients: a pooled analysis. Ther Adv Med Oncol. 2024; 16, 17588359241271913.
|
| [16] |
Chen Y, Jia K, Xie Y, et al. The current landscape of gastric cancer and gastroesophageal junction cancer diagnosis and treatment in China: a comprehensive nationwide cohort analysis. J Hematol Oncol. 2025; 18, 42.
|
| [17] |
Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376, 687-697.
|
| [18] |
Janjigian YY, Kawazoe A, Bai Y, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023; 402, 2197-2208.
|
| [19] |
Peng Z, Liu T, Wei J, et al. Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study. Cancer Commun. 2021; 41, 1173-1182.
|
| [20] |
Shitara K, Bang YJ, Iwasa S, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020; 382, 2419-2430.
|
| [21] |
Takahari D, Kawazoe A, Machida N, et al. Phase 2 study of trastuzumab deruxtecan as neoadjuvant treatment for HER2-positive gastric and gastroesophageal junction adenocarcinoma (EPOC2003). J Clin Oncol. 2024; 42, 309.
|
| [22] |
Rivera F, Izquierdo-Manuel M, Garcia-Alfonso P, et al. Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial. Eur J Cancer. 2021; 145, 158-167.
|
| [23] |
Janjigian YY, Al-Batran SE, Wainberg ZA, et al. Perioperative durvalumab in gastric and gastroesophageal junction cancer. N Engl J Med. 2025; 393, 217-230.
|
| [24] |
Xu Y, Wang Y, Gong J, et al. Phase I study of the recombinant humanized anti-HER2 monoclonal antibody‒MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors. Gastric Cancer. 2021; 24, 913-925.
|
| [25] |
Dong S, Wei C, Wang X, et al. A retrospective multicenter study on the efficacy and safety of disitamab vedotin monotherapy versus combination with anti-PD-1 immunotherapy in advanced gastric cancer. Sci Rep. 2025; 15, 2232.
|
| [26] |
Liu L, Li S, Liu Z, et al. Disitamab vedotin (RC48), tislelizumab, and S-1 as first-line therapy for HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): updated results from the RCTS trial. J Clin Oncol. 2025; 43, 4059-4059.
|
| [27] |
Zhang M, Ding C, Xu L, et al. Comparison of a tumor-ratio-metastasis staging system and the 8th AJCC TNM staging system for gastric cancer. Front Oncol. 2021; 11, 595421.
|
| [28] |
Rüschoff J, Hanna W, Bilous M, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol. 2012; 25, 637-650.
|
| [29] |
Terp SK, Guldbrandsen K, Stoico MP, et al. Genome-wide cfDNA methylation profiling reveals robust hypermethylation signatures in ovarian cancer. Cancers (Basel). 2025; 17, 2026.
|
| [30] |
Alsina M, Arrazubi V, Diez M, Tabernero J. Current developments in gastric cancer: from molecular profiling to treatment strategy. Nat Rev Gastroenterol Hepatol. 2023; 20, 155-170.
|
| [31] |
Tokunaga M, Machida N, Mizusawa J, et al. Early endpoints of a randomized phase II trial of preoperative chemotherapy with S-1/CDDP with or without trastuzumab followed by surgery for HER2-positive resectable gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301C (Trigger Study). Gastric Cancer. 2024; 27, 580-589.
|
| [32] |
Wagner AD, Grabsch H, Mauer MEL, et al. Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2 positive gastric (GC) and esophagogastric junction cancer (EGJC): first results of the EORTC 1203 INNOVATION study, in collaboration with the Korean Cancer Study Group, and the Dutch Upper GI Cancer group. J Clin Oncol. 2023; 41: 4057.
|
| [33] |
Jiang H, Yu X, Li N, et al. Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study. J Immunother Cancer. 2022; 10:e003635.
|
| [34] |
Li N, Li Z, Fu Q, et al. Efficacy and safety of neoadjuvant sintilimab in combination with FLOT chemotherapy in patients with HER2-negative locally advanced gastric or gastroesophageal junction adenocarcinoma: an investigator-initiated, single-arm, open-label, phase II study. Int J Surg. 2024; 110, 2071-2084.
|
| [35] |
Peng Z, Zhang X, Liang H, et al. Atezolizumab and trastuzumab plus chemotherapy for ERBB2-positive locally advanced resectable gastric cancer: a randomized clinical trial. JAMA Oncol. 2025; 11: 619-624.
|
| [36] |
Dumontet C, Reichert JM, Senter PD, Lambert JM, Beck A. Antibody‒drug conjugates come of age in oncology. Nat Rev Drug Discov. 2023; 22, 641-661.
|
| [37] |
Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov. 2023; 22, 101-126.
|
| [38] |
Chen Y, Jia K, Sun Y, et al. Predicting response to immunotherapy in gastric cancer via multi-dimensional analyses of the tumour immune microenvironment. Nat Commun. 2022; 13, 4851.
|
| [39] |
Pourjamal N, Le Joncour V, Vereb G, et al. Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan. Transl Oncol. 2025; 53, 102284.
|
| [40] |
Hu Y, Zhu Y, Wei X, Tang C, Zhang W. Disitamab vedotin, a novel HER2-directed antibody‒drug conjugate in gastric cancer and other solid tumors. Drugs Today. 2022; 58, 491-507.
|
| [41] |
Yao X, Jiang J, Wang X, et al. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity. Breast Cancer Res Treat. 2015; 153, 123-133.
|
| [42] |
Li H, Yu C, Jiang J, et al. An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer. Cancer Biol Ther. 2016; 17, 346-354.
|
| [43] |
Shitara K, Van Cutsem E, Bang YJ, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol. 2020; 6, 1571-1580.
|
| [44] |
Wainberg ZA, Fuchs CS, Tabernero J, et al. Efficacy of pembrolizumab monotherapy for advanced gastric/gastroesophageal junction cancer with programmed death ligand 1 combined positive score >/=10. Clin Cancer Res. 2021; 27, 1923-1931.
|
| [45] |
Wang Y, Gong J, Wang A, et al. Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial. EClinicalMedicine 2024; 68, 102415.
|
| [46] |
Narita Y, Mizuno T, Ishizuka Y, et al. Clinicopathological and prognostic significance of HER2-low expression in advanced gastric cancer: a retrospective observational study. Oncologist. 2025; 30:oyae328.
|
| [47] |
Shimozaki K, Fukuoka S, Ooki A, Yamaguchi K. HER2-low gastric cancer: is the subgroup targetable? ESMO Open. 2024; 9, 103679.
|
| [48] |
Zaanan A, Didelot A, Broudin C, et al. Longitudinal circulating tumor DNA analysis during treatment of locally advanced resectable gastric or gastroesophageal junction adenocarcinoma: the PLAGAST prospective biomarker study. Nat Commun. 2025; 16, 6815.
|
| [49] |
Iden CR, Mustafa SM, Øgaard N, et al. Circulating tumor DNA predicts recurrence and survival in patients with resectable gastric and gastroesophageal junction cancer. Gastric Cancer. 2025; 28: 83-95.
|
| [50] |
Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020; 31: 745-759.
|
| [51] |
Yang J, Gong Y, Lam VK, et al. Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer. Cell Death Dis. 2020; 11: 346.
|
| [52] |
Wong J, Muralidhar R, Wang L, Huang C-C. Epigenetic modifications of cfDNA in liquid biopsy for the cancer care continuum. Biomed J. 2025; 48:100718.
|
| [53] |
Pandey S, Yadav P. Liquid biopsy in cancer management: integrating diagnostics and clinical applications. Pract Lab Med. 2025; 43:e00446.
|
| [54] |
Clements HA, Underwood TJ, Petty RD. Total neoadjuvant therapy in oesophageal and gastro-oesophageal junctional adenocarcinoma. Br J Cancer. 2024; 130: 9-18.
|
RIGHTS & PERMISSIONS
2026 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.
PDF
(2854KB)
